Cost of Revenue Comparison: Zoetis Inc. vs ACADIA Pharmaceuticals Inc.

Zoetis vs. ACADIA: A Decade of Cost Dynamics

__timestamp	ACADIA Pharmaceuticals Inc.	Zoetis Inc.
Wednesday, January 1, 2014	60602000	1717000000
Thursday, January 1, 2015	76369000	1738000000
Friday, January 1, 2016	4406000	1666000000
Sunday, January 1, 2017	13060000	1775000000
Monday, January 1, 2018	18330000	1911000000
Tuesday, January 1, 2019	19598000	1992000000
Wednesday, January 1, 2020	20550000	2057000000
Friday, January 1, 2021	19141000	2303000000
Saturday, January 1, 2022	10166000	2454000000
Sunday, January 1, 2023	45731000	2710000000
Monday, January 1, 2024		2719000000

Data in motion

Cost of Revenue: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. This chart compares the cost of revenue for Zoetis Inc. and ACADIA Pharmaceuticals Inc. from 2014 to 2023. Zoetis, a leader in animal health, consistently shows a robust cost of revenue, peaking at $2.71 billion in 2023, reflecting a 58% increase from 2014. In contrast, ACADIA, focused on neurological treatments, exhibits a more volatile pattern, with costs fluctuating significantly, peaking at $76 million in 2015. This disparity highlights Zoetis's stable growth and market dominance, while ACADIA's variability suggests strategic shifts or market challenges. Such insights are invaluable for investors and industry analysts aiming to understand financial health and strategic positioning in the pharmaceutical sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025